CD274 and non-small cell lung carcinoma: Following this model, in silico clinical trial simulation of PD-L1 inhibition (durvalumab) used virtual patients, whose data closely matched real patient information, to predict checkpoint inhibitor efficacy in stage III NSCLC (Table 2).